StreetAlpha.app
Home › Stocks › SRZN

Surrozen, Inc. (SRZN)

Healthcare
$29.98
▼ −7.24%
LAST CLOSE · NOV 17

Surrozen develops antibody-based therapies that target the Wnt pathway, with a focus on eye diseases. It last closed at $29.98 on Nov 17, down 7.24% on the day. The average 12-month price target from 3 analysts is $65.33 (+117.9% from the last close), with a high of $80.00 and a low of $54.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is SRZN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$10.5M
+192.1% vs a year ago
Net income
−$390.2M
−3706.4% margin
EPS (diluted)
−$41.94
Free cash flow
−$30.8M
−292.3% margin
Valuation
Market cap
$571.5M
19.1M shares
P/E
–
No P/E while losing money
Price to sales
54.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$100.4M
At Sep 30
Shareholder equity
−$335.6M
Shares outstanding
19.1M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $12.5M$12.5MFY2022FY2023: $0$0FY2023FY2024: $10.7M$10.7MFY2024FY2025: $3.5M$3.5MFY2025

From SRZN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on SRZN in the past 90 days
Average 12-month target
$65.33
▲ 117.9% upside

Based on 3 analysts who set a price target on SRZN in the past 90 days. The average target is $65.33, with a high of $80.00 and a low of $54.00, compared with the last close of $29.98.

Low $54.00Avg $65.33High $80.00
Blue marker: last close $29.98
Highest target$80.00
Average target$65.33
Lowest target$54.00
Latest rating changes
GuggenheimMaintained
Nov 12Buy$80
Cantor FitzgeraldMaintained
Nov 10Buy$62
HC Wainwright & Co.Target raised
Sep 25Buy$44 → $54
HC Wainwright & Co.Reiterated
Aug 10Buy$44
DateFirmActionRatingPrice target
Nov 12GuggenheimMaintainedBuy$80
Nov 10Cantor FitzgeraldMaintainedBuy$62
Sep 25HC Wainwright & Co.Target raisedBuy$44 → $54
Aug 10HC Wainwright & Co.ReiteratedBuy$44
Loading…

Technical Analysis

SRZN · as of the Nov 17 close · updated after every close
Uptrend

The stock is 1% above its 20 day and 12% above its 50 day average. It is 14% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 53). The nearest support is the 20 day average at $29.75, and the nearest resistance the Pivot at $30.39.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 7.8%/day
Key levels
$37.8352 week high+26.2%
$31.47Pivot R1+5.0%
$30.97Swing high (Oct 9)+3.3%
$30.39Pivot+1.4%
$29.98Last close
$29.7520 day average−0.8%
$28.89Pivot S1−3.6%
$26.2850 day average−12.3%
$25.73200 day average−14.2%
$25.00Swing low (May 20)−16.6%
$24.55100 day average−18.1%
$12.5252 week low−58.2%
Indicators
RSI (14)52.61Middle of its rangeNeutral
MACD1.50Below its signal lineBearish
Stochastic60.4Middle of its rangeNeutral
ADX (14)33.0Trending up
Williams %R-62.4Oversold below −80, overbought above −20Neutral
CCI (20)24.1Oversold below −100, overbought above 100Neutral
Rate of change−0.5%Change over 10 sessionsBearish
ATR (14)$2.35Typical daily range, 7.8% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for SRZN

What happened before

See how SRZN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SRZN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SRZN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SRZN in the last 90 days.

Loading…

See today’s whale options flow across the market →

SRZN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲62 buying vs 45 selling
  • ▲Held by funds +1.4 pts
  • ▲Funds holding +9
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9485+10.6%
In funds' top 1067−14.3%
Held by funds82.3%80.9%+1.4 pts
New / increased35 / 2727 / 20+31.9%
Reduced / sold out18 / 2712 / 17+55.2%
Put/call ratio1.790.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SRZN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SRZN is in one of them and how their past SRZN trades turned out.

SRZN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SRZN in an article yet. Here's the latest on the wider market.

About Surrozen

Surrozen is a biotechnology company based in South San Francisco, California. It develops antibody-based drug candidates that act on the Wnt pathway, a signaling system involved in tissue repair. Its main focus is eye disease, with candidates in development for diabetic macular edema and the wet form of macular degeneration, conditions treated by eye specialists. The company also has a development agreement with Boehringer Ingelheim for a related candidate.

Headquarters
South San Francisco, CA